Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization

M. T. Martin-Iverson, S. M. Stahl, S. D. Iversen

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The locomotor stimulant effects of sustained administration of a potent and selective dopamine (DA) D-2 receptor agonist, [+]-4-propyl-9-hydroxynaphthoxazine (PHNO), in rats were assessed 24 h a day during 12 h light-dark cycles. PHNO was administered continuously with subcutaneous implants of Alzet osmotic minipumps (5 μg/h), for 12 h a day with modified osmotic minipumps (5 μg/h), or by daily injections (15 μg, SC). Tolerance was observed to occur only with 24 h continuous infusions and only during the light period. The other treatment regimens produced sensitization of the locomotor response. Daytime tolerance to continuous infusions of PHNO was reversed following reversal of the light-dark cycle. A normally 'arousing' stimulus also reversed (temporarily) daytime tolerance. The present results indicate that the temporal pattern of administration of DA agonists, the phase of the circadian cycle and environmental stimuli associated with arousal are important determinants of the behavioral consequences of long-term treatment.

Original languageEnglish
Pages (from-to)534-539
Number of pages6
JournalPsychopharmacology
Volume95
Issue number4
DOIs
Publication statusPublished - 1 Aug 1988
Externally publishedYes

Fingerprint

Photoperiod
Dopamine
Dopamine Agonists
Arousal
Light
Injections
Therapeutics
naxagolide

Cite this

@article{b736f34e285d4ef4a3f18dfa903d7684,
title = "Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization",
abstract = "The locomotor stimulant effects of sustained administration of a potent and selective dopamine (DA) D-2 receptor agonist, [+]-4-propyl-9-hydroxynaphthoxazine (PHNO), in rats were assessed 24 h a day during 12 h light-dark cycles. PHNO was administered continuously with subcutaneous implants of Alzet osmotic minipumps (5 μg/h), for 12 h a day with modified osmotic minipumps (5 μg/h), or by daily injections (15 μg, SC). Tolerance was observed to occur only with 24 h continuous infusions and only during the light period. The other treatment regimens produced sensitization of the locomotor response. Daytime tolerance to continuous infusions of PHNO was reversed following reversal of the light-dark cycle. A normally 'arousing' stimulus also reversed (temporarily) daytime tolerance. The present results indicate that the temporal pattern of administration of DA agonists, the phase of the circadian cycle and environmental stimuli associated with arousal are important determinants of the behavioral consequences of long-term treatment.",
keywords = "Circadian rhythms, D-2 receptors, Dopamine agonist, Locomotor activity, PHNO, Rats, Sensitization, Stress, Tolerance",
author = "Martin-Iverson, {M. T.} and Stahl, {S. M.} and Iversen, {S. D.}",
year = "1988",
month = "8",
day = "1",
doi = "10.1007/BF00172969",
language = "English",
volume = "95",
pages = "534--539",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer-Verlag London Ltd.",
number = "4",

}

Chronic administration of a selective dopamine D-2 agonist : factors determining behavioral tolerance and sensitization. / Martin-Iverson, M. T.; Stahl, S. M.; Iversen, S. D.

In: Psychopharmacology, Vol. 95, No. 4, 01.08.1988, p. 534-539.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic administration of a selective dopamine D-2 agonist

T2 - factors determining behavioral tolerance and sensitization

AU - Martin-Iverson, M. T.

AU - Stahl, S. M.

AU - Iversen, S. D.

PY - 1988/8/1

Y1 - 1988/8/1

N2 - The locomotor stimulant effects of sustained administration of a potent and selective dopamine (DA) D-2 receptor agonist, [+]-4-propyl-9-hydroxynaphthoxazine (PHNO), in rats were assessed 24 h a day during 12 h light-dark cycles. PHNO was administered continuously with subcutaneous implants of Alzet osmotic minipumps (5 μg/h), for 12 h a day with modified osmotic minipumps (5 μg/h), or by daily injections (15 μg, SC). Tolerance was observed to occur only with 24 h continuous infusions and only during the light period. The other treatment regimens produced sensitization of the locomotor response. Daytime tolerance to continuous infusions of PHNO was reversed following reversal of the light-dark cycle. A normally 'arousing' stimulus also reversed (temporarily) daytime tolerance. The present results indicate that the temporal pattern of administration of DA agonists, the phase of the circadian cycle and environmental stimuli associated with arousal are important determinants of the behavioral consequences of long-term treatment.

AB - The locomotor stimulant effects of sustained administration of a potent and selective dopamine (DA) D-2 receptor agonist, [+]-4-propyl-9-hydroxynaphthoxazine (PHNO), in rats were assessed 24 h a day during 12 h light-dark cycles. PHNO was administered continuously with subcutaneous implants of Alzet osmotic minipumps (5 μg/h), for 12 h a day with modified osmotic minipumps (5 μg/h), or by daily injections (15 μg, SC). Tolerance was observed to occur only with 24 h continuous infusions and only during the light period. The other treatment regimens produced sensitization of the locomotor response. Daytime tolerance to continuous infusions of PHNO was reversed following reversal of the light-dark cycle. A normally 'arousing' stimulus also reversed (temporarily) daytime tolerance. The present results indicate that the temporal pattern of administration of DA agonists, the phase of the circadian cycle and environmental stimuli associated with arousal are important determinants of the behavioral consequences of long-term treatment.

KW - Circadian rhythms

KW - D-2 receptors

KW - Dopamine agonist

KW - Locomotor activity

KW - PHNO

KW - Rats

KW - Sensitization

KW - Stress

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0023706589&partnerID=8YFLogxK

U2 - 10.1007/BF00172969

DO - 10.1007/BF00172969

M3 - Article

VL - 95

SP - 534

EP - 539

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -